Business Description
TME Pharma NV
ISIN : NL0015000YE1
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.29 | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-Equity | -14.29 | |||||
Debt-to-EBITDA | -0.35 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -10.8 | |||||
3-Year EPS without NRI Growth Rate | -18.6 | |||||
3-Year FCF Growth Rate | 35.5 | |||||
3-Year Book Growth Rate | 62.6 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.45 | |||||
9-Day RSI | 32.28 | |||||
14-Day RSI | 38.33 | |||||
6-1 Month Momentum % | -5.52 | |||||
12-1 Month Momentum % | -77.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.91 | |||||
Quick Ratio | 0.91 | |||||
Cash Ratio | 0.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -136.4 | |||||
Shareholder Yield % | -23.72 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -3158.21 | |||||
ROA % | -149.5 | |||||
ROIC % | -212.04 | |||||
ROC (Joel Greenblatt) % | -4733.26 | |||||
ROCE % | -2344.66 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.95 | |||||
EV-to-EBITDA | -0.97 | |||||
EV-to-FCF | -0.66 | |||||
Earnings Yield (Greenblatt) % | -105.26 | |||||
FCF Yield % | -137.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TME Pharma NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.248 | ||
Beta | 1.1 | ||
Volatility % | 107.84 | ||
14-Day RSI | 38.33 | ||
14-Day ATR (€) | 0.027855 | ||
20-Day SMA (€) | 0.27575 | ||
12-1 Month Momentum % | -77.52 | ||
52-Week Range (€) | 0.1902 - 1.994217 | ||
Shares Outstanding (Mil) | 28.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TME Pharma NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TME Pharma NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
TME Pharma NV Frequently Asked Questions
What is TME Pharma NV(XPAR:ALTME)'s stock price today?
When is next earnings date of TME Pharma NV(XPAR:ALTME)?
Does TME Pharma NV(XPAR:ALTME) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |